Related Experiment Video

Updated: Feb 28, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

5.9K

[Prognostic value of biomarkers in chronic heart failure with preserved left ventricular ejection fraction]

T A Nikiforova1, D Yu Shchekochikhin1, F Yu Kopylov1

  • 1I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia.

Terapevticheskii Arkhiv
|June 22, 2017
PubMed

Insights

This review covers key biomarkers for chronic heart failure with preserved ejection fraction prognosis. Cystatin C is highlighted as a novel and practically important biomarker for patient outcomes.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Chronic heart failure with preserved ejection fraction (HFpEF) presents a significant clinical challenge.
  • Accurate prognostic assessment is crucial for guiding patient management and therapeutic strategies in HFpEF.
  • Current prognostic tools require refinement to better stratify HFpEF patient risk.

Purpose of the Study:

  • To review established and emerging biomarkers for predicting prognosis in patients with HFpEF.
  • To evaluate the clinical utility and potential of novel biomarkers, specifically cystatin C, in HFpEF prognostication.

Main Methods:

  • Comprehensive literature review of studies identifying biomarkers for HFpEF prognosis.
  • Analysis of data on established prognostic markers in HFpEF.
  • Focused review on the role and evidence for cystatin C as a prognostic biomarker in HFpEF.

Main Results:

  • Several biomarkers are associated with prognosis in HFpEF, including natriuretic peptides and cardiac biomarkers.
  • Cystatin C emerges as a promising novel biomarker, demonstrating strong correlations with adverse outcomes.
  • The practical application of cystatin C in routine clinical practice for HFpEF is discussed.

Conclusions:

  • Biomarker-guided prognostication is essential for optimizing care in HFpEF.
  • Cystatin C represents a significant advancement in prognostic assessment for HFpEF patients.
  • Further research and validation are warranted to fully integrate cystatin C into clinical guidelines for HFpEF.

Keywords:
chronic heart failure with preserved ejection fraction; natriuretic peptide; galectin-3; urodilatin; C-type natriuretic peptide (CNP); D-type natriuretic peptide; cystatin C; growth- stimulating factor (ST2)

More Related Videos

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

8.7K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

692

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
651
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
998
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
482
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
719